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ABSTRACT 
 
 
Fatal Familial Insomnia is a rare genetic disorder affecting about 27 families worldwide, 
caused by mutations in the prion protein gene PRNP. Symptoms include loss of sleep and 
disrupted circadian rhythms. The function of PNRP in circadian rhythms is not well understood. 
The goal of this project was to create a cellular PRNP gene knockout and test the effects on 
circadian proteins using novel circadian luciferase reporter assays. The results indicate that one 
CRISPR-treated WI-38 cell line contains a disrupted coding region for PRNP, so this cell line 
can be used in future experiments to observe potential alterations in the expression of several 
cellular circadian rhythm proteins in the absence of PRNP.  The results also show that luciferase 
plasmid hPer-2 works well to monitor circadian rhythm in U-2 OS cells, which validates the use 
of these novel reporters for studying circadian rhythm. 
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BACKGROUND 
 
 
Prion Diseases 
 
Prion diseases are a set of progressive fatal neurodegenerative illnesses that belong to the 
Transmissible Spongiform Encephalopathies (TSE) and manifest themselves in vertebrates 
(Prusiner and Dearmond, 1994). They are distinguished by long incubation periods, multi-focal 
spongiform pathology in the brain associated with neuronal loss, and a failure to induce an 
inflammatory response.  In humans, these diseases can be either sporadic or familial (inherited), 
and include Creutzfeldt-Jakob disease (CJD), Fatal Familial Insomnia (FFI), Gerstmann-
Straussler-Schienker (GSS) disease, and Kuru (Montagna, 2005).  Symptoms vary widely, but 
can include rapidly progressive dementia, visual abnormalities, and cerebellar dysfunction, 
including muscle incoordination, and gait and speech abnormalities. During the course of the 
disease, many patients develop pyramidal and extrapyramidal dysfunction including abnormal 
reflexes, spasticity, tremors, and rigidity.  Some patients may also show behavioral changes such 
as agitation, depression, or confusion. These symptoms often deteriorate into an akinetic mutism 
in the final fatal stage. 
Prion diseases are a type of protein misfolding disease caused by the conversion of prion 
protein cellular (Prp
C
) to infectious prion protein scrapie (PrP
Sc
), the latter is a misfolded version 
of PrP
C
 characterized by high β-sheet content (Prusiner and Dearmond, 1994). Accumulations of 
Prp
Sc
 in the brain have been found to induce neural degeneration related to disease symptoms 
and onset, however, the exact mechanisms of pathogen propagation are not well understood 
(Montagna, 2011). This MQP project focused on the prion protein and its gene PRNP in relation 
to FFI and circadian rhythms.  
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Fatal Familial Insomnia 
 
FFI is a rare, autosomal dominant, prion disease that has been reported in about 27 
kindreds worldwide (Montagna, 2011). It is caused by a mutation in PRNP at codon 178 that 
results in a D178N substitution, and a polymorphism at codon 129 (Montagna et al., 2003). FFI 
onset can range from 36 to 62 years, with a mean onset age of 51 years, and can have either a 
short disease duration of less than 11 months, or a prolonged disease duration of greater than 11 
months (Montagna, 2011). Initial symptoms typically include the inability to nap or fall asleep, 
visual fatigue, and autonomic hyperactivity. As the disease progresses, symptoms include 
complete loss of sleep ability, oneiric stupors, motor impairment, and mental confusion, with 
later symptoms of akinetic mutism and emaciation, eventually resulting in death (Montagna, 
2005). Studies have found that FFI symptoms are most likely caused by the accumulation of 
PrP
Sc
 in the thalamus and brain, which causes neuronal loss and spongiosis (Montagna et al., 
2003).  
As is typical of the other spongiform diseases, the mechanism of FFI is not well 
understood. Many of the symptoms associated with FFI are related to sleep and circadian 
rhythm, suggesting a possible role for PrP
C
 in sleep regulation and circadian rhythm (Montagna, 
2005). However, the prion protein gene PRNP and PrP in both cellular and pathogenic forms 
have not been extensively studied, hindering our understanding of FFI and potential therapies.  
 
PrP
C
 and PrP
Sc
 Structure 
 
PrP
C
 is composed of approximately 45% α-helix and lacks β-sheet structures (Figure-1, 
right panel). The converted form PrP
Sc
 (Figure-1, left panel) contains approximately 30% α-
helix and 45% β-sheet (Huang et al., 1996). The two forms differ in that PrPC is soluble and 
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susceptible to degradation by proteases, while PrP
Sc
 is insoluble and protease resistant. The 
actual method of PrP
C
 conversion to PrP
Sc
 is not well understood.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1: Theoretical 3-Dimensional Structures of Proteins PrP
Sc
 and PrP
C
.  
PrP
Sc
 is shown on the left panel, and PrP
C
 in the right panel.  The α-helical 
domains are shown as gray spirals, while the β-sheets are shown as flat arrows.  
The green and red arrows in the left panel represent β-sheets, which were 
converted from the corresponding colored helix in the right panel of PrP
C
. Note 
that the right structure for PrP
C
 lacks β-sheets.  (Huang et al., 1996) 
 
 
 
Circadian Rhythm  
 
Since many of the FFI symptoms are related to sleep and circadian rhythm, PrP
C
 may 
itself affect these biological processes.  Daily cycles and changes in the physiological and 
behavioral characteristics of organisms constitute their circadian rhythm. These cycles entrain 
organisms to a specific, endogenous pattern aligned with day and night cycles, synchronizing 
their internal and external environments (Vitaterna et al., 2001). Circadian rhythm is controlled 
primarily by the circadian system, or circadian clock, with localized clocks also found 
throughout the body in peripheral cells, tissues, and organs (Hida et al., 2012). In mammals, the 
circadian clock is ultimately regulated by the suprachiasmatic nucleus (SCN), located in the 
hypothalamus, which serves as a central oscillator, that synchronizes all localized clocks to one 
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circadian rhythm based on environmental cues (Buhr and Takahashi, 2013). Through 
synchronization of internal clocks with external environmental cues, the circadian clock system 
is able to regulate daily physiological rhythms, such as the sleep-wake cycle, body temperature, 
hormone secretion, and other physiological processes.  
 
Circadian Rhythm at the Molecular Level 
The circadian clock system functions through the expression of clock genes and their 
transcription factors, which together form positive and negative transcriptional feedback loops 
(Figure-2).   In the nucleus, clock genes brain and muscle ARNT-like protein 1 (BMAL1) and  
circadian locomotor output cycles kaput (CLOCK) form a positive auto regulatory loop by 
forming a heterodimer that binds to E-box CACGTG enhancers, activating the transcription of 
genes period (PER1, PER2) and cryptochrome (CRY1, CRY2), which form the negative 
regulatory loop of the clock mechanism. Once PER and CRY genes are activated, PER and CRY 
RNA molecules begin to accumulate in the cytoplasm, forming PER-CRY dimers. The PER-
CRY dimers then translocate into the nucleus, where they bind to the BMAL1-CLOCK 
heterodimer, thus repressing the activation of PER and CRY genes (Nagoshi, et al.). In order for 
a new transcription cycle to begin, PER and CRY must be regulated for degradation. 5’ 
adenosine monophosphate-activated protein kinase (AMPK) and casein kinase 1 (CK1ε/δ) 
phosphorylate PER and CRY, targeting them for ubiquitination and degradation through the 26S 
proteasome, allowing for BMAL1 and CLOCK to be activated.  
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Figure-2: Schematic of the Mammalian Circadian Clock.  The blue and 
green ovals represent BMAL1 and CLOCK heterodimers, which initiate 
transcription of clock genes PER and CRY, represented by the yellow and 
orange ovals, respectively. PER and CRY form a heterodimer that inhibits 
transcription by the BMAL1-CLOCK heterodimer. PER and CRY are then 
degraded by AMPK, CK1, and polyubiquitins. (Buhr and Takahashi, 2013) 
 
In addition to this regulatory mechanism, binding of the BMAL1-CLOCK heterodimer 
also activates transcription of nuclear receptor Rev-erb-α and nuclear receptor retinoid-related 
orphan receptor (ROR-α), which regulate BMAL1 through stimulation by ROR-α and repression 
by Rev-erb-α. Accumulation of Rev-erb-α represses BMAL1, with the overall stimulation and 
repression of BMAL1 forming a 12 hour peak in RNA levels that are out of phase with PER and 
CRY transcription products (Reppert and Weaver, 2002). Altogether, the repression and 
activation of the clock genes constitute a 24-hour mammalian circadian cycle.  
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Disruptions in the Circadian Rhythm  
Circadian rhythm is intimately linked with different physiological processes, such as, but 
not limited to, the sleep-wake cycle, metabolism, body temperature, and hormone secretion. 
Disruptions in circadian rhythm caused by the misalignment of endogenous internal circadian 
clocks relative to the external environment have been shown to affect cognitive function and 
sleep, and may result in circadian rhythm sleep disorders (CRSD) (Dodson and Zee, 2010). Such 
disorders include advanced sleep phase disorder, delayed sleep phase disorder, non-24 hour 
sleep-wake disorder, and others caused by the disruption of certain clock genes. Delayed sleep 
phase disorder has the phenotype of late sleep times between 2 AM and 6 AM, and delayed wake 
times, typically late morning to early afternoon, and although the mechanism is not exactly 
known, it is believed that polymorphisms in the genes CLOCK and PER cause the disorder. 
Similarly, advanced sleep phase disorder manifests as a sleep time between 7 PM to 9PM, and a 
wake time typically before 5 AM (Jones et al., 1999). The exact cause of advanced sleep phase 
syndrome is also not known, but studies of the disorder have found two families with gene 
mutations of PER2 and casein kinase I delta (CSNK1D), respectively, demonstrating a genetic 
basis to the disorder (Dodzon and Zee, 2010). Additional studies in mice have also begun to 
show evidence for altered neuronal behavior at the cellular level caused by circadian rhythm 
disruptions due to gene mutations in Per, demonstrating the possibility that altered circadian 
rhythm may play a role in cognitive decline or impairment (Wang et al., 2009).  
 
 
PRNP and Circadian Rhythm  
 
Studies have found that sleep loss or disrupted circadian rhythms may be caused by 
mutations in PRNP, demonstrating that PrP
C
 may play an important role in circadian rhythm 
pathways. In one study, 24-hour recordings of core-body temperatures, heart rate, mean arterial 
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pressure, norepinephrine, and cortisol and melatonin concentrations in FFI patients showed 
differences between the patients and controls (Figure-3) (Montagna et al., 2003).  In the healthy 
control, melatonin, which plays a role in the sleep-wake cycle, rises sharply during the dark 
period. In comparison, the FFI patient has consistently low melatonin levels throughout day and 
night, demonstrating how a change in circadian rhythm may also affect sleep, with progressive 
sleep loss being one of FFI’s main symptoms.  
 
Figure-3: Twenty Four Hour Study of FFI Patients vs. Healthy Controls. 
FFI patients are represented as filled black circles and healthy controls are 
represented as non-filled diamonds.  24-hour recordings began at time 16:00, 
with the black bar representing dark periods.  (Montagna et al., 2003) 
 
In another study, PRNP knockout mice were raised and observed for differences in 
development and neurophysiology (Tobler et al., 1996). Mice lacking PRNP developed and 
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reproduced normally, showing no deficiencies or impairments. Circadian rhythm was observed 
through the use of running wheels to gage motor activity rhythms under light dark conditions. It 
was found that PRNP-deficient mice had altered, longer, period lengths when compared to wild 
type mice, suggesting that PrP
C
 may have a direct role in normal circadian rhythm functions 
(Tobler et al., 1996).  
Although the exact function of PRNP in relation to circadian rhythm is unknown, 
learning how PRNP affects circadian rhythm physiologically and molecularly is a key to 
understanding the cause and related symptoms of prion diseases, such as fatal familial insomnia.  
 
 
CRISPR Genome Editing  
 
The creation of a PRNP knockout in human cell lines for the purpose of identifying 
changes in cellular circadian rhythm is an integral part of this MQP project. Genome editing is 
the process of making targeted DNA mutations using tools to cut and then incorporate mutations 
of interest through homologous or non-homologous DNA recombination. These tools include 
zinc finger nucleases (ZFNs), transcription activator like effector nucleases (TALENs), and more 
recently, clustered regularly interspersed short palindromic repeats (CRISPR) (Figure-4). Of the 
three methodologies mentioned, CRISPRs are the newest. We chose to use the CRISPR system 
for performing the knockout in WI-38 cell lines because of its ease of design and high efficiency. 
The CRISPR and CRISPR associated (Cas) is a natural defense system found in bacteria and 
archae, where the CRISPR is used to recognize invading phage DNA and plasmid DNA by 
incorporating sequences from the invading phage in a small RNA-based repertoire, that is then 
used for further recognition and destruction of the foreign genetic elements through DNA 
cleavage (Horvath and Barrangou, 2010; Karginov and Hannon, 2010; Wiedenheft et al., 2012).  
As a genome-editing tool, the CRISPR/Cas system functions in a similar manner to that of the 
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bacterial defense system. The CRISPR/Cas system requires a Cas nuclease, such as cas9 (green 
in the diagram), CRISPR RNA (crRNA) (orange in the diagram), and a guide RNA (blue in the 
diagram). The crRNA guides the Cas9 nuclease to a specific DNA sequence and a double-
stranded break is induced.  For gene removal, two guide RNAs can be designed to target the Cas 
nuclease to sites flanking the gene targeted for removal, and then the DNA ends are rejoined in 
vivo by DNA ligase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4: Diagram of the Three Main Methodologies for Genome Editing.  Shown are the 
three main techniques currently used for genomic editing, including zinc finger nucleases (Panel-
A), Talens (Panel-B), and CRISPRs (Panel-C). In the case of the CRISPR system, a guide RNA 
(blue in the diagram) is used to target the Cas-9 nuclease (green) to induce a double-stranded cut.  
Two cuts can be designed to excise a specific gene, and then the DNA ends are resealed in vivo by 
DNA ligase.  (Addgene's Guide to CRISPR Technologies, 2013) 
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PROJECT PURPOSE 
 
 Fatal familial insomnia (FFI) is a rare prion disorder caused by mutations in the PRNP 
gene, and affects approximately 27 families worldwide.  Of the various symptoms associated 
with FFI, a loss of circadian rhythm has been found to be detrimental to patients. Although it is 
known that mutations in PRNP can result in FFI, it is not well understood whether normal WT 
PRNP plays a role in circadian rhythm, and whether the mutations associated with FFI affect 
circadian rhythm, causing further disorder progression. The purpose of this project was to 
develop and utilize novel cellular assays to determine whether a PRNP gene knockout disrupts 
circadian rhythm, implicating a role for PRNP in circadian rhythm.  The CRISPR system will be 
used to create PRNP knockouts in WI-38 cell lines, and the effects on various circadian proteins 
will be assayed using luciferase reporters with circadian protein promoters. 
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METHODS 
 
Exome Variant Server FFI Assessment 
 In order to find the prevalence of the FFI mutations in a general population, PRNP was 
queried for variants using the Exome Variant Server (EVS). Under Data Browser in the EVS, 
PRNP was queried using gene information from the National Center for Biotechnology 
Information (NCBI). Data sets for both African American and European American populations 
were selected and downloaded as text files. Text files were converted to spread sheet format and 
analyzed for PRNP mutations related to FFI.   
 
Creating a CRISPR 
 In order to create a CRISPR that targets and creates a gene knockout (KO) in PRNP, a 
target guide RNA as well as sense and antisense oligos with vector specific overhangs were 
designed and ordered from Invitrogen. Oligos were annealed using a PCR program that heats 
samples to a high temperature, and then it slowly lowers the temperature to allow for natural 
formation of double stranded DNA.  The samples were treated with polynucleotide kinase (PNK) 
after being annealed in order to add a phosphate to the 5’ end. The annealed oligos were ligated 
into backbone vector px330, a vector consisting of a chimeric guide RNA and Cas9 nuclease.  
The resulting plasmid was then transformed into E. coli bacteria in preparation for sequencing. 
Chosen colonies were prepared using the Qiagen Mini Prep Kit, and sequenced using the U6 
promoter forward primer in order to confirm the desired crRNA. A total of three PRNP CRISPR 
plasmids were made, identified as PRNP CRISPR 1, 2, and 3, and were transfected into WI-38 
cells.  
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Cell Culture and Maintenance  
 The WI-38 (ATCC® CCL-75™) cell line is derived from human fetal lung tissue. We used it 
as a transfection host for the PRNP KO CRISPR due to its genomic stability. WI-38 cells were 
grown in Eagle’s Minimum Essential Media (EMEM), supplemented with 2 mM L-glutamine 
and a final concentration of 1% non-essential amino acids (NEAA) and 15% fetal bovine serum 
(FBS). WI-38 cells were plated from a frozen stock, and passaged 1:2 once a high confluence 
had been reached. Cells were transfected 4-5 days later using the Optifect WI-38 transfection kit 
(Life Technologies) once 80% or greater confluence had been achieved.  
 
Optifect WI-38 Cell Transfection  
 WI-38 cells were pre-plated onto a 6 well plate with a cell volume of 250,000 cells per 
well.  Plasmid DNAs for GFP (control) and PRNP KO’s were mixed with a lipid-based 
transfection reagent and incubated at room temperature for 15 minutes before being added drop-
wise to the pre-plated cells. Once the DNA and reagent were added to the wells, the volume was 
raised to a total volume of 1.0 mL using Optimem media. For maintenance, cells were cultured 
after the transfection with puromycin and EMEM in order to place selective pressure on the cells.  
 
CRISPR Efficacy Testing 
In order to test the efficacy of the designed CRISPRs, CRISPRs were transfected into 
WI-38 cells. Cells were grown after transfection for approximately 48 hours, after which 
genomic DNA was extracted using the Qiagen DNeasy kit for blood and animal cells. Once the 
DNA was extracted, genomic regions expected to contain the CRISPR-induced mutations were 
amplified using PCR and run on a gel. The amplicon was excised from the gel and purified using 
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the Qiagen Gel Extraction kit. Amplicons were subsequently denatured and reannealed using the 
Surveyor Assay (described below).  
 
Surveyor Assay 
 Genomic DNA (gDNA) was isolated from WI-38 cells transfected with plasmids PRNP 
CRISPR 1, 2, or 3, using the DNeasy WI-38 DNA extraction kit for blood and animal cells. The 
gDNA CRISPR insertion site was amplified using PCR. The PCR product was then annealed and 
processed using the Surveyor Mutation Detection Kit.  If the CRISPR plasmid successfully 
induced a mutation at its target site, the isolated gDNA will contain both WT and mutant type 
amplicons.  If WT DNA anneals with mutant DNA, a DNA mismatch will occur, and the 
amplicon will be sensitive to digestion with a single-strand-specific Surveyor nuclease. The final 
surveyor products were run on a 2% agarose TBE gel alongside the original WT amplicon to 
determine whether any of the CRISPR plasmids had induced any PRNP mutations. The original 
amplicon is approximately 600 bp in length and a possible mutation site occurs at position of 200 
bp. If a mismatch is present, this will result in a 200 bp fragment plus a 400 bp fragment in the 
sample lane. 
 
Gel Mutation Assay 
 A second assay for identifying potential mutations in the PRNP CRISPR transfected WI-
38 cells is a Gel Mutation Assay.  This was performed using gDNA isolated from from WI-38 
cells treated with PRNP CRISPR 1, 2, or 3. Using PCR, a 100 bp region near the CRISPR 
insertion site was amplified from the gDNA.  The PCR product was then run on a 4% agarose 
TBE gel and analyzed for possible insertions or deletions, which would present as smaller or 
larger bands in the sample lanes.  
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Circadian Luciferase Reporter Assay 
Four plasmids received from the Weitz lab at Harvard Medical School were transfected 
into a U-2 OS (ATCC® HTB-96™) cell line in order to test synchronization using different 
conditions, as well as to evaluate the ability of the circadian reporter plasmids. The four plasmids 
consisted of an hPer2 promoter short fragment, the first two kb of the hBmal1b-promoter, the 
first two kb of the mPer1 promoter, and the first two kb of the mPer2 promoter, upstream from 
the luciferase reporter gene. Transfected cells were pre-plated in a 96 well plate at a cell density 
of approximately 3 x 10
6
 cells per well, under four different synchronization methods, no 
synchronization media, Forskolin, Dexamethasone, and serum shock, and then incubated. After 
incubation, the medium was aspirated from each cell and replaced with phenol red-free medium 
containing 0.1 μM luciferin. The plate was then sealed using a plastic plate cover and vacuum 
grease to prevent the media from evaporating during the assay. Cells were placed in a Tecan 
Infinite 200 Pro plate reader at 37° Celsius, with luciferase readings taken every 8 minutes for 5 
days for a total of 960 time points.  
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RESULTS 
 
 
 FFI is a rare genetic disorder caused by mutations in the PRNP gene. Of the many 
symptoms associated with FFI, loss of circadian rhythm and sleep are most detrimental to 
patients. In order to better understand the role of PRNP in circadian rhythm, we created PRNP 
KO’s using the CRISPR/Cas system, and tested novel circadian rhythm assays to assess whether 
circadian rhythm behaviors of cells could be measured quantitatively. These assays represent the 
preliminary stages of a future project that will test whether circadian proteins are altered in cells 
containing PRNP mutations or in cells completely lacking PRNP.  
 
Transfection Optimization 
To introduce genetic mutations into the genome of WI-38 cells, we first need to introduce 
CRISPR plasmids using lipid-mediated transfection.  We first optimized our transfection 
protocol using WI-38 cells.  A cell optimization test was performed to find the optimal number 
of cells needed for transfection and the optimal amount of reagent required for the highest 
transfection rate.  Conditions were tested using three different cell densities, either pre-plated 
prior to lipid addition, or plated simultaneously with lipid addition, using two different lipid 
concentrations, and using two different plasmid masses (Figure-5).  A green fluorescent protein 
(GFP) plasmid was used for this test transfection, allowing transfected cells to easily be observed 
under a microscope.  GFP-positive cell counts performed for the different reactions showed that 
reaction four, which contained 1.0 μg of DNA and 1.0 μl of transfection reagent, for both pre-
plating prior to lipid addition and plating with simultaneous lipid addition under all cell seed 
numbers, had the highest transfection rates when compared to the other three reactions under 
similar plating and cell seed number conditions.   
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Figure-5: Experimental Design of WI-38 Transfection Optimization 
Conditions. Shown above are the conditions used to optimize the transfection 
conditions for WI-38 cells.  The location of each reaction in the table specifies 
the constituents of the reaction. For example, Reaction 1 under the light green 
shading on the left (50,000 cells seeded) in the pre-plated box contains 0.5 μl of 
transfection reagent and 0.5 μg of DNA.  
  
 
In order to assess whether pre-plating the cells prior to lipid addition or adding the lipid 
simultaneous to plating is best, three cell counts were taken of random fields of the transfected 
cells. This data confirmed that pre-plating the cells prior to lipid addition generally produced 
higher levels of transfection (Table-1).  Cells pre-plated at a cell density of 65,000 cells 
produced an average transfection percentage of 22.7% with the smallest standard deviation (best 
reproducibility) compared to other transfection conditions that may have had a higher 
transfection percentage.  Combining the results of Figure-5 and Table-I, it was determined that 
WI-38 cells transfect optimally using 65,000 cells pre-plated prior to lipid addition, and a total of 
1.0 μg of DNA and 1.0 μl of transfection reagent. These optimized transfection conditions were 
used later on the WI-38 cells when transfecting the PRNP KO CRISPR plasmids. 
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Table-1. Transfected Cell Field Counts of Reaction Four.  GFP-positive cell 
counts from cells plated using Reaction 4 of the optimized transfection 
conditions were conducted on random fields directly comparing pre-plated cells 
versus simultaneous addition of the lipid at different cell densities.     
 
Test of Circadian Rhythm Plasmids 
To determine whether cellular circadian rhythm could be measured using the provided 
reporter plasmids, a luciferase assay was designed that focused on cell synchronization methods 
and luciferase expression driven by the promoter of core circadian clock genes. The assay was 
designed according to previously established methods that use human U-2 OS cells to monitor 
circadian clock rhythms in vitro (Vollmers et al., 2008).  We tested the synchronization methods 
and reporter plasmids in the U-2 OS cell line which is known to express circadian rhythms.  U-2 
OS cells transfect efficiently and do not require the optimized transfection protocol described 
above for the WI-38 cells.  U-2 OS cells were plated at a cell density of 250,000 cells per well in 
a 96-well plate and were transfected with circadian rhythm reporter plasmids for human and 
mouse circadian proteins. To determine the best method of cell synchronization, four conditions 
were tested: forskolin, dexamathosone, serum shock, or untreated cell media (no 
synchronization). Cells were transfected with reporter plasmid, incubated with one of the four 
conditions, and then assayed for luciferase activity using a plate reader every eight minutes over 
five days for a total of 960 time points. Cells transfected with plasmid hPer2-luc confirmed that 
circadian rhythm could be measured (Figure-6). At periods where hPer2 was active, luciferase 
was also activated, as shown by several re-occurring peaks.   All other luciferase reporter 
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plasmids tested did not produce detectable levels of rhythm, and showed no re-occurring peaks 
in the graphed data. All four cell synchronization methods produced similar results, indicating 
that any synchronization can be used in future experiments with the PNRP knockout cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-6: U-2 OS hPER2 Circadian Luciferase Assay Results. Four different 
cell synchronization methods were compared: blue (no synchronization),  red 
(Forskolin), green (Dexamethasone), and purple (serum shock). The photon rate 
was determined every eight minutes over five days. 
 
 
CRISPR Knockout of PRNP 
To determine whether the PRNP gene can be knocked out in WI-38 cells using our 
CRISPR methodology, a target RNA was designed against the PRNP gene to create a KO.  We 
created three PRNP CRISPR plasmids and focused on exon-2 of the PRNP gene as it contains 
the transcriptional start site.  By selecting a CRISPR target sequence before the exon-2 start 
codon (Figure-7), the CRISPR/Cas system will induce a frame shift mutation if successful.  
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Figure-7: PRNP CRISPR Graphic Map and Insertion Sites. Using molecular 
biology software, the insertion sites of PRNP CRISPR 1 and 2 are shown. Pink 
indicates the exon regions of the PRNP gene, blue indicates the protein-coding 
region, and green indicates the CRISPR.  
 
 
The three PRNP CRISPR plasmids, designated PRNP-1, PRNP-2, and PRNP-3, were 
transfected into WI-38 cells using the optimized transfection protocol described above. The WI-
38 cells were placed under selective pressure using puromycin to select for CRISPR-positive 
cells. To determine whether the PRNP CRISPR plasmids caused the expected mutations in the 
PRNP gene, the genomic DNA (gDNA) from each population of WI-38 cells was extracted, the 
target site was amplified by PCR, and the amplicons were analyzed using a gel mutation assay 
(Figure-8). The gel mutation assay was performed to observe whether any mutations such as 
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deletions or insertions are present in the PRNP KO gDNA samples at the target sites.  Any 
mutations greater than about 5 bp will be observed as a shift in band mobility relative to WT.  
The data indicates that possible mutations occurred using PRNP KO CRISPRs 2 and 3, as 
visualized using Primer set-2 (black arrows, left side of the figure).  
 
 
 
 
 
 
 
 
 
 
 
Figure-8: Gel Mutation Assay of PRNP KO’s. Three different PRNP KO 
gDNA’s were tested: PRNP-1, PRNP-2, and PRNP-3. Two different primer sets 
were used, PRNP Mutation 1 (right side of figure) and PRNP Mutation 2 (left 
side of figure).  BMAL 1 gDNA was used as a control in both primer sets and 
with an additional BMAL 1 primer set. Arrows indicate the smaller bands likely 
harboring deletion-type mutations.  
 
The surveyor assay (Figure-9) was performed as a backup assay for identifying CRISPR-
induced mutations.  The Surveyor assay identifies mutations in a different manner, and was 
performed to compare possible mutations found between the Surveyor assay and the gel 
mutation assay. In the Surveyor assay, a 600 bp PCR amplicon from the WT and potentially 
mutated target sites are mixed, denatured, reannealed, and cut with a single-strand-specific 
Surveyor nuclease. If a mutation is present in the CRISPR-treated DNA, a mismatch occurs in 
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the formed heteroduplex, making the DNA sensitive to digestion with Surveyor nuclease.  A 
potential mutation site exists at 200 bp from the left terminus of the 600 bp amplicon, so if that 
mutation is present, cleavage by the Surveyor nuclease would result in the formation of a 200 bp 
band and a 400 bp band in the lane.  Unfortunately, the Surveyor assay data was inconclusive. 
The PCR failed to amplify the PRNP region of interest for several different reactions, and the 
positive control reaction also failed.  Thus, this assay needs to be redone.   
 
 
Figure-9: Surveyor Assay Results.  Three different CRISPR PRNP KO 
gDNA’s were used in this assay: PRNP-1, PRNP-2, and PRNP-3. Two different 
primer sets were used, PRNP Surveyor-1 (right side), and PRNP Surveyor-2 
(left side).  BMAL-1 gDNA was used as a control in both primer sets and with 
an additional BMAL-1 Surveyor primer set. Surveyor PRNP samples were run 
on a 2% agarose gel alongside the respective PCR product.  
 
 
 
Although the Surveyor assay did not work, the gel mutation assay identified two potential 
positives created by CRISPR’s 2 and 3, so those two potentially mutated amplicons were cloned 
and sequenced.  The PRNP KO DNA amplicons were ligated into a plasmid and transformed 
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into E. coli. The plasmid DNA was then extracted from the E. coli using the Qiagen MiniPrep 
Kit and sequenced. The sequencing results were then aligned with the WT PRNP coding region 
to assess whether mutations were present (Figure-10).  We sequenced 25 colonies and 
discovered one insertion, indicating that our PRNP CRISPRs can yield mutations in the PRNP 
gene of the WI-38 cell line.  
 
   
 
 
Figure-10:  Sequence Analysis of Potential PRNP Mutants.  The figure 
shows the alignment of WT PRNP DNA (upper row) versus 13 clones of the 
PCR amplicons from WI-38 gDNA treated with CRISPR’s 2 and 3.   Genomic 
DNA was isolated from cells transfected with the PRNP CRISPRs targeting 
exon 2 of the PRNP gene.  The PRNP target location was amplified, cloned, and 
sequenced.  Each sequence represents the genome of one WI-38 cell.  One cell 
contains an inserted sequence at the target site (red), which is a candidate for 
future studies investigating the consequences of loss of functional PRNP on 
circadian characteristics.   
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DISCUSSION 
 
 
 The goal of this project was to assess the potential effects of the PRNP gene on circadian 
rhythm by creating a PRNP knockout in WI-38 cells using the CRISPR/Cas system, and 
assaying the PRNP-KO cells for the levels of various circadian rhythm proteins using luciferase 
reporter plasmids. Using the CRISPR/Cas system, the data indicate that we created a frame shift 
mutation in the genome of one WI-38 cell, indicating the designed PRNP CRISPR is capable of 
editing the PRNP gene in the genome of WI-38 cells. The results also show that a reporter 
plasmid for hPer-2 circadian protein can successfully monitor circadian rhythm in U-2 OS cells, 
and in the future this assay will hopefully allow for analysis of circadian behavior of WI-38 cells 
bearing CRISPR-mediated PRNP gene KO’s.  
 Fatal familial insomnia (FFI) is a rare autosomal dominant disease that is highly 
penetrant and fatal in those affected by the disease. FFI is caused by mutations in PRNP, which 
result in the misfolding of prion protein from a normal cellular form to a pathogenic form. Of the 
associated symptoms, loss of circadian rhythm is apparent (Montagna et al., 2003). However, it 
is unknown whether PRNP loss or mutations associated with FFI affect the cellular levels of 
various circadian proteins.  In order to understand whether PRNP plays a role in circadian 
rhythms, the CRISPR/Cas genome editing system was used to create a KO in the PRNP gene in 
WI-38 cells. Designed PRNP CRISPRs were transfected into WI-38 cells, and subsequent 
screening identified one WI-38 cell line with the expected insertion in exon-2 of PRNP.   
Previous studies observed robust circadian oscillations in human U-2 OS cells using luciferase 
reporter plasmids driven by promoters from circadian proteins (Vollmers et al., 2008). Using 
similar procedures, we tested two human circadian promoters, hPER2 and hBMAL1, and two 
mouse circadian promoters, mPer1 and mPer2.  The data indicated that of the four circadian 
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promoters tested, only the hPer2 promoter successfully demonstrated circadian rhythm in the U-
2 OS cells. But at least this shows that cellular circadian rhythm can be successfully measured 
using the luciferase reporter approach.  
 Although the overall goal of the project was to assay whether a PRNP-KO affects cellular 
circadian rhythm, the assays conducted in this project represent vital preliminary steps needed to 
begin to understand the role that PRNP may have in circadian rhythm. The genome of one WI-38 
cell was successfully mutated using the designed PRNP CRISPR, showing that this designed 
plasmid works well. In the future, this KO cell line will be grown to a monoclonal population, 
and western blots will be performed to verify the PRNP protein has been knocked down.  The 
KO cells will then be transfected with a designed luciferase reporter plasmid and assayed for 
alterations in circadian protein levels.  If WI-38 cells fail to show a circadian rhythm, the PRNP 
KO will be repeated in other cell lines of interest.  Ultimately, various FFI PRNP mutations will 
be created to determine whether they show the same phenotype as the PRNP KO.  
In general, this project encountered two main challenges. First, the WI-38 cells proved 
difficult to transfect, and they grew slowly. The transfection assay was optimized for these cells, 
however, even with optimized conditions, many of the WI-38 cell populations failed to grow or 
transfect, perhaps due to the primary-like nature of WI-38 cells.  Although the circadian 
luciferase assay worked well for U-2 OS cells, it failed to detect a circadian rhythm in WI-38 
cells, so the assay will need to be repeated.  This project used novel CRISPR and luciferase 
circadian protein assays, each of which had to be perfected before we are able to perform the 
final test of circadian rhythms in PRNP KO cells. In addition, the FFI project is novel to our 
laboratory.  It is also very time consuming to prepare monoclonal populations of WI-38 cells.   
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